Mirum Pharmaceuticals, Inc.

Vice President, Commercial Operations International

Mirum Pharmaceuticals, Inc.  •  Zug, CH (Hybrid)  •  2 hours ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

MISSION

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.

POSTION SUMMARY

Aa core member of the International Leadership, this position plays a key strategic and operational role within International Region. The Vice President Commercial Operations will lead International Regions in all aspects of commercialization and business performance: strategy, brand planning process, tactical execution, launch readiness and execution, operational excellence and delivering on established KPIs. This position will be key in driving the commercialization of the company’s existing portfolio and upcoming launches. The individual will work closely with cross-functional team across the organization.

JOB FUNCTIONS/RESPONSIBILITIES

  • Develop and execute the International commercial strategy in alignment with global priorities.
  • Lead end-to-end launch excellence across International markets, including readiness planning, resource allocation, market sequencing, and post-launch performance optimization.
  • Help build the Mirum culture by serving as an effective bridge between International and US teams.
  • Ensure execution of all operational business activities to maximize patient access and commercial impact.
  • Lead regional marketing and commercial operations team
  • Ensure the critical linkage across commercial, medical affairs, regulatory affairs, market access, finances, compliance and to support all partners in executing best in-class operational activities.
  • Continuously assess productivity and efficiency of commercial organization, lead commercial operating model strategic thinking across markets – directly or in close collaboration with partners.
  • Drive initiatives to prepare for further sustainable growth in International: commercial KPIs benchmarking, business plan, sales plans and forecasting models, marketing tactics, etc.
  • Prioritize key strategic initiatives in collaboration with global / International leadership team and other stakeholders to build optimal organization that enables long term sustainable growth.
  • Partner for all global Business development opportunities assessment in the region.
  • Ensure adherence to all relevant legal, regulatory and compliance requirements, corporate policies and procedures.

QUALIFICATIONS

Education/Experience:

  • Extensive expertise in the pharmaceutical/biotech commercial operations, in multiple healthcare systems, especially in European markets.
  • Proven successful experience in operational commercial role at regional as well as local country level.
  • Hands-on involvement in the development of commercial strategy, etc.
  • Rare or ultra-rare disease experience preferred.
  • Good understanding of commercial, access and regulatory process.
  • Undergraduate degree required, MBA and/or relevant postgraduate qualifications preferred.
  • 15+ years experience in life sciences, start up, biotech or pharma industry, in marketing/commercial functions.
  • Eligibility to work in Switzerland (valid Swiss work permit) is required.

Knowledge, Skills and Abilities:

  • Strong strategic thinking and capacity to execute strategy in a variety of business environment in International region.
  • Able to drive initiatives and lead new projects in a lean organization by working cross functionally and using key stakeholders’ areas of expertise.
  • Enjoy building and creating and is a self-starter.
  • Highly organized and comfortable managing multiple work streams at once.
  • Exceptional communication and interpersonal skills.
  • Great attention to detail and self-motivation.
  • Willingness to travel internationally

#LI-HYBRID

Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.

Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

Industry
Chemicals & Materials
Company Size
201-500 employees
Headquarters
Foster City, CA
Year Founded
2018
Social Media